Related Experiment Video
Updated: Jan 3, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
1Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract:
Mutations of FLT3 occur in around a third of acute myeloid leukemia (AML) patients and are associated with poor outcomes. Multiple targeted tyrosine kinase inhibitors (TKI) have been developed with different selectivity and potency for FLT3 mutant clones. Indications for which FLT3 inhibitor to use depend on the clinical setting and disease status. Patients with relapsed or refractory AML benefit from a different TKI than those with de novo AML or following stem cell transplant. Moreover, each FLT3 TKI displays a different toxicity and inhibitory profile and may be most useful in patients with varying comorbidities and types of FLT3 mutations.
Insights
FLT3 mutations are common in acute myeloid leukemia (AML) and linked to poor prognosis. Choosing the right FLT3 inhibitor depends on the patient
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- * FLT3 mutations are present in about one-third of acute myeloid leukemia (AML) cases.
- * These mutations are associated with unfavorable patient outcomes.
- * Various targeted tyrosine kinase inhibitors (TKIs) exist, differing in selectivity and potency against FLT3 mutant clones.
Purpose of the Study:
- * To review the clinical indications for selecting specific FLT3 inhibitors in AML treatment.
- * To highlight how clinical setting and disease status influence TKI choice.
- * To discuss the varying toxicity and inhibitory profiles of FLT3 TKIs.
Main Methods:
- * Review of current literature on FLT3 inhibitors in AML.
- * Analysis of clinical trial data and treatment guidelines.
- * Comparison of TKI selectivity, potency, and toxicity profiles.
Main Results:
- * Different FLT3 TKIs are indicated for distinct clinical scenarios, including de novo AML, relapsed/refractory AML, and post-stem cell transplant settings.
- * Patient comorbidities and specific FLT3 mutation types influence the optimal TKI selection.
- * Each TKI exhibits a unique toxicity and inhibition profile, necessitating individualized treatment approaches.
Conclusions:
- * The choice of FLT3 inhibitor in AML requires careful consideration of the patient's clinical context, disease status, and individual mutation characteristics.
- * Tailoring TKI therapy based on these factors is crucial for optimizing treatment efficacy and managing toxicity.
- * Further research into personalized FLT3 inhibitor selection strategies is warranted.
